Purpose: Few features characterizing the dosimetric properties of the patients are included in currently available dose-volume histogram (DVH) prediction models, making it intractable to build a correlative relationship between the input and output parameters. Here, we use planning target volume (PTV)-only treatment plans of the patients (i.e., the achievable dose distribution in the absence of organs-at-risk (OAR) constraints) to estimate the potentially achievable quality of treatment plans and establish a machine learning-based DVH prediction framework with the use of the dosimetric metric as model input parameters. Methods: A support vector regression (SVR) approach was used as the backbone of our machine learning model. A database containing volumetric modulated arc therapy (VMAT) plans of 63 prostate cancer patients were used. For each patient, the PTV-only plan was generated first. A correlative relationship between the OAR DVH of the PTV-only plan (model input) and the corresponding DVH of the clinical treatment plan (CTP) (model output) was then established with the 53 training cases. The prediction model was tested by the validation cohort of ten cases. Results: For the training cohort, the checks of dosimetric endpoints (DEs) indicated that 52 of 53 plans (98%) were within the 10% error bound for bladder, and 45 of 53 plans (85%) were within the 10% error bound for rectum. In the validation tests, 92% and 96% of the DEs were within the 10% error bounds for bladder and rectum, respectively, and eight of ten validation plans (80%) were within the 10% error bound for both the bladder and rectum. The sum of absolute residuals (SAR) achieved a mean of 0.034 AE 0.028 and 0.046 AE 0.021 for the bladder and rectum, respectively. Conclusions: A novel dosimetric features-driven machine learning model with the use of PTV-only plan has been established for DVH prediction. The framework is capable of efficiently generating best achievable DVHs for VMAT planning.
INTRODUCTION
The development of intensity-modulated radiation therapy (IMRT) 1, 2 and volumetric modulated arc therapy (VMAT) 3, 4 provides us with remarkable ability to maximize radiation dose to the planning target volume (PTV) while sparing for the critical organs-at-risk (OAR). [5] [6] [7] In the IMRT and VMAT workflow, the design of a patient-specific treatment planning is a critical step. Unfortunately, the planning process routinely used in the clinic remains time consuming and labor intensive, involving multiple manual trial-and-errors to obtain a clinically acceptable plan. 8 Prior knowledge-based planning (KBP) [9] [10] [11] [12] [13] [14] has been studied to automate the plan selection process or to predict achievable plan/optimization parameters such as the dose-volume histograms (DVHs) of the OARs for a new case through machine learning algorithms or searching population-based plan libraries.
An accurate prediction of achievable DVHs on a patientspecific basis would greatly improve IMRT/VMAT planning in both efficiency and quality. An essence in establishing a predictive model is the choice of model input parameters correlative to the final treatment plan. Up to now, the predictive models rely heavily on the use of geometric and anatomical features of the OARs and target volumes. In these models, the efforts have been devoted to correlating the DVHs of OARs of the resultant plans to specific geometric or anatomical features. [15] [16] [17] [18] Specifically, Wu et al. 15 employed the overlap volume histogram (OVH) to predict DVHs of OARs using the spatial configuration of an OAR to a target. Zhu et al. 16 used the distance-to-target histogram (DTH) as a geometric feature to train the model for the prediction of DVHs. Appenzoller et al. 8 proposed an achievable DVH prediction method by employing the skew-normal probability distribution to fit subvolume dose distributions. More recently, Song et al. 17 developed a method of predicting the patient-specific dosimetric endpoints (DEs) based on the differential distance-to-target histogram (dDTH). Wall et al. 18 incorporated the in-field volume into the OVH to reduce the distance-to-dose correlation variation and demonstrated that the method can produce more precise and achievable dose prediction for knowledge-based planning.
Geometric/anatomical features play important roles in the construction of prediction models, and existing KBP-based methods have demonstrated the effectiveness of using geometric/anatomic features for DVH prediction. However, the strategy has pitfalls. While it is generally true that the resultant DVHs depend on the anatomy, the number of anatomical features that influence OAR dose sparing is rather large and may not be sufficient in establishing a reliable predictive model, especially in the presence of tissue density heterogeneities. In reality, the interpatient variations in these anatomical features and their impact on the resultant OAR doses are very complicated. Given the complexity of the dose or DVH prediction problem at hand, it may become an intractable task to find an array of well-quantified anatomical features to accurately predict achievable dose sparing for each OAR. In addition, few features characterizing the patients' dosimetric properties have been used in the existing prediction models, and merely using geometric/anatomical features to construct a prediction model may lead to suboptimal prediction.
The holy grail in dealing with the issue of DVH prediction here is to find the most descriptive features of the system. For the prediction of best achievable DVHs for a given patient, there are obviously many types of input properties that may influence the resultant treatment plan. In general, the input parameters should be uniquely descriptive of the resultant plan, straightforward to obtain, and easily extendable to all disease sites. Instead of using the geometric/anatomical features or the features from the clinical treatment plan (CTP) of the patient, we seek additional relevant properties that are not part of the input data but may be more descriptive of the final solution for the patient. For this purpose, we examine the feasibility of using the inherent capability (or the inherent likelihood) for the given case to meet the dosimetric goals as the input features and establish a machine learning predictive model. For a given RT modality and beam configuration, the differential dosimetric capability represents a priori knowledge of the system once the patient is chosen, and a detailed description on how to quantify intrapatient dosimetric capability and how to integrate the data into the inverse planning process was presented in Shou et al. 19 While it is possible to aggregate voxel dosimetric capability to quantitatively describe intrapatient variation in the capability, here we propose to measure the dosimetric capability by relying on the PTV-only VMAT plan, which provides the best scenario of targeting the tumor and worst scenario of sparing for OARs, that is, the achievable dose distribution in the absence of OAR constraints. The logic behind the proposed method is that the difference in achievable OAR DVHs in the PTV-only plans for different patients reflects the OAR geometric/ anatomical difference. The DVHs of PTV-only plans not only explicitly provide dosimetric features but also implicitly encode the inherent information related to geometric/ anatomical features. A PTV-only plan is a strong indicator of what would be achievable in the final plan optimization and can serve as an input feature for the machine learning predictive model. The rationale is that, if it is far away from the clinical goals, the case is a "tough" one and it would be difficult to generate a plan that meets all clinical constraints.
The purpose of this work is to formally establish such a dosimetric capability-based machine learning approach for reliable prediction of the achievable DVHs of OARs. In this framework, the best achievable OAR DVHs are derived based on the input information of the DVHs from the PTVonly plans. Compared with current geometric/anatomical features-based approaches, the proposed approach alleviates the complicated process of quantifying anatomical features and harnesses directly the inherent correlation between the PTV-only plan and the clinical plan in the dose domain. By leveraging the high-level dosimetric correlation, the proposed approach promises to better model the system and provide a more robust and efficient solution to the important DVH prediction problem in treatment planning and plan quality assurance (QA).
MATERIALS AND METHODS

2.A. Prediction pipeline
The study consists of two main tasks: (a) prediction model construction and (b) model validation. An overview of the pipeline is presented in Fig. 1 . Briefly, we first leverage on the high-level correlation between the DVHs of the PTV-only plan and the corresponding CTP and develop a robust predictive model. The input for training such a prediction model includes a database of prior clinical plans and the corresponding PTV-only plans. After training, a series of validation tests are performed.
2.B. Plan database and RapidPlan model configuration
In this work, we compared the proposed prediction model with the RapidPlan model, which is a knowledgebased treatment planning tool available in Varian Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA) for DVH prediction of OARs to facilitate IMRT and VMAT treatment planning. The RapidPlan model is built based on the geometric/anatomical features including the distance-to-target histogram, OAR volume, target volume, overlapping volume, out-of-field volume, etc. In contrast, our prediction model is constructed using the dosimetric features. Both our proposed prediction model and Rapid Plan model were trained on the same set of 53 prostate cancer plans. In addition, ten patients were randomly selected as an independent validation cohort. All these patients were treated between 2015 and 2018 by a single radiation oncologist following our institutional procedure and VMAT planning protocol using the Varian Eclipse treatment planning system (TPS). All the plans utilized two coplanar arcs, and dose prescriptions for clinically treated plans were 80 Gy in 40 fractions. The prostate and 1.5 cm of proximal seminal vesicles were defined as clinical target volume (CTV). PTV was created with a margin of 5 mm posteriorly and 8 mm in all other directions to CTV. For clinical plans, OARs included rectum, bladder, femoral heads, anal canal, penile bulb, corporal bodies and bowel. The rectum was delineated from sigmoid flexure to the bottom of ischial tuberosities.
The planning objectives for PTV, rectum and bladder are listed in Table I . Specifically, for the PTV, all the plans were normalized such that 95% of the PTV volume was covered by 100% of the prescription dose. In addition to dosimetric objectives specified in Table I , the following constraints needed to be met: (a) the entirety of CTV + 5 mm posterior margin volume should receive 100% of the prescription dose, and (b) 50% isodose line (IDL) should transverse the half of anterior/posterior extent of the rectum to ensure adequate rectum sparing without sacrificing CTV coverage when considering daily anatomical variations of prostate and rectum.
In addition to the clinical plan, we also generated a simple PTV-only VMAT plan for each patient, using the same beam settings in the clinical plan. In PTV-only treatment planning, we focused on the PTV performance (PTV coverage, PTV dose homogeneity, dose conformity, and dose drop-off outside the PTV) and ignored the requirements of all OARs by treating them as normal tissues and not giving them specific constraints. A normal tissue objective (NTO) was kept as the same as that in the clinical plan to ensure PTV dose conformity and dose drop-off outside the PTV. The PTV-only plan here represents the best PTV performance plan by releasing the constraints of the involved OARs. The resultant OAR DVHs in the PTV-only plans depend on the relative geometric relations among the PTV and OARs. A prediction model based on the correlation between the DVHs of the PTV-only plans and those of the CTPs can be used to predict OAR DVHs for a new patient. The optimization of the PTV-only plan was performed in the Varian Eclipse TPS as follows. First, the beam settings and normal tissue constraints were configured to be identical to those in the clinical plan of the patient. We then set the two PTV constraints, including an upper constraint of 82 Gy with a priority of 100 and a lower constraint of 80 Gy with the same priority. The NTO parameters in Eclipse were typically set as this: priority of 150, distance from target border of 0.2 cm, start dose of 100%, end dose of 65% and fall-off of 0.2. Note that the OAR constraints were not applied.
The predicted DVHs by the dose-based KBP method were compared with that predicted by the geometric/ anatomical features-based RapidPlan model for assessing the feasibility and effectiveness of the proposed prediction model. All the predicted DVHs, either from our model or the RapidPlan, were directly from the outputs of the prediction model.
2.C. Prediction model
The prediction model was built by using support vector regression (SVR) 20 to correlate the DVHs of the PTV-only plan and the CTP. As a counterpart of the support vector machine (SVM), 21 SVR is used for regression problems. SVM/SVR are supervised learning models which build a hyperplane to separate data belonging to different classes by solving a quadratic optimization problem to maximize the margin between hyperplane and training data. For data that are not linearly separable, a kernel function is introduced to project the data into a higher dimensional space such that the projected data become linearly separable. In this study, SVR was selected from a number of existing machine learning methods as the backbone of the proposed prediction model for its known robustness, accuracy, and computational efficiency. We can use the SVR models to construct the submodels for predicting the DEs of the DVH. In our DVH prediction setting, each submodel is built for predicting one DE in the DVH. Suppose a sequence of DEs for a DVH is denoted by D.below:
where d i denotes the dose and V d represents the volume. For a PTV-only plan, its DVH can be represented by a sequence of DEs:
Likewise, a DVH of the corresponding clinical plan can be denoted by the following sequence of DEs:
The submodel for the prediction of the i-th DE D i of the DVH is represented by M i , and the training data learned for the submodel M i is represented as follows:
denote the i-th DE in the j-th DVH of the PTV-only plan and the i-th DE in the j-th DVH of the clinical plan, respectively. After each of submodels are built, the final high-level DVH prediction model M is constructed by integrating the above submodels:
In such a way, the resultant high-level prediction model M is trained to model the correlation between the DVH in the PTV-only plan and the DVH in the clinical plan. Thus, for each OAR, a high-level prediction model is built for prediction of the OAR DVH.
2.D. Model validation and improvement of the training datasets
The accuracy of the prediction model is checked through the residual analysis. The difference between the predicted DVHs and CTP DVHs can be quantified by the sum of absolute residuals (SAR), as given below:
where D denotes the dose, DD represents the discrete dose bin, DVH C and DVH P denote the DVH of clinical plan and the predicted DVH, respectively. In order to improve the prediction capability, the constructed prediction model can be refined. The refinement process includes: (a) identification of suboptimal plans; and (b) exclusion of the identified suboptimal plans from current training cohort. The restricted sum of residuals (RSR) 8 is employed to identify the suboptimal plans. The RSR between the DVH C and DVH P is formulated as:
where ɛ(D) is given as follows: 
The potential suboptimal plan is identified when the RSR between DVH C and DVH P is large. In this work, the RSR is considered to be large if the RSR is greater than the sum of the mean and standard deviation (i.e., RSR þ r) for the RSR values in the dataset. To confirm that the plan with large RSR value is suboptimal, replanning is carried out for those plans with large RSR values. Replans were generated by an experienced dosimetrist to examine if there is any space to improve in OARs sparing while keeping similar PTV dose coverage and dose uniformity. Refinement of the plan was done when the above situation was found to be the case. During the process of replanning, the predicted values were not provided to the dosimetrist for reference. The achievable DVH improvement after replanning with respect to the original CTP is quantified by the following sum of absolute residuals DSAR:
where DVH R ðDÞ denotes the DVH of the replan. The identified suboptimal CTPs are excluded from current training FIG. 6 . Comparison between the DVH of RapidPlan and the predicted DVH in the proposed method for the rectum on ten validation cases. The orange, green, and blue curves represent the DVHs of clinical plan, RapidPlan, and the predicted result of our proposed method, respectively. [Color figure can be viewed at wileyonlinelibrary.com] cohort, and the corresponding replans serve as the surrogates. The updated cohort of plans are used for learning a refined prediction model. Figure 2 shows the dose distributions and bladder and rectum DVHs of CTPs and PTV-only plans for two example cases from the training database. As can be seen from Fig. 2 , the DVH differences between the two plans are case dependent and their values depend on the complicated geometrical relationship between PTV and the OARs, such as overlapping volume of the PTV and OAR, distance to PTV, PTV volume, and OAR volume.
RESULTS
The proposed prediction model was evaluated via residual analysis. Statistical analysis for the training cohort yielded the mean and standard deviation of SAR 0.023AE 0.011 for bladder and 0.044 AE 0.020 for rectum, indicating the strong correlative relationship between the DVHs of the PTV-only plans and those of the CTPs. Figure 3 compares the DEs, that is, V 18 , V 30 , V 60 , V 80 , and D mean for bladder, and V 15 , V 45 , V 65 , V 80 , and D mean for rectum between the predicted DVHs and the CTP DVHs for the training cohort. DE checks indicated that 52 of 53 plans (98%) were within the 10% error bound for bladder, and 45 of 53 plans (85%) were within the 10% error bound for rectum. Figure 4 compares the DEs between the predicted DVHs and the CTP DVHs for the ten validation cases. The results demonstrated that for most cases the DE values in the predicted DVHs were close to those in the CTP DVHs for both bladder and rectum. Noteworthly, 92% and 96% of the points were within the 10% error bounds, which correspond to 10% OAR volume of the bladder and rectum, as shown in Fig. 4 . We found that the DE values in eight of ten validation plans (80%) were completely within the 10% error bound for both bladder and rectum.
In Figs. 5 and 6, we compared our predicted DVHs with those predicted by RapidPlan and the CTP DVHs for the ten validation cases. The CTP DVHs, RapidPlan, and our prediction are represented by the orange, green, and blue curves, respectively. As shown in Fig. 5 , the predicted DVHs of our proposed method for the bladder are closer to the CTP DVHs than those of RapidPlan for most cases. Likewise, for the rectum, our prediction model generated the DVHs which are closer to the CTP DVHs than those of the RapidPlan on ten validation cases for almost all of the cases, as displayed in Fig. 6 . Table II shows the results of residual analysis for ten validation cases. The bladder model in the proposed method achieved the mean and standard deviation of SAR 0.034AE 0.028, as compared with 0.038AE 0.014 by the RapidPlan. The rectum model in the proposed method obtained the mean and standard deviation of SAR 0.046AE 0.021 in contrast to 0.078AE 0.039 by the RapidPlan. This shows the effectiveness and better performance of the proposed method in predicting the achievable DVHs. We also computed the average dose of the CTP, RapidPlan, and our predicted DVHs for each validation case. The mean differences in the average dose between CTP and our prediction for bladder and rectum were 2.4 and 2.0 Gy, respectively, as compared to 3.1 and 9.6 Gy, respectively, between the CTP and RapidPlan. These results demonstrated that the average doses in our predicted DVHs are closer to the CTP DVHs than that of the RapidPlan prediction.
Based on the analysis of the RSR values, two plans were identified as suboptimal with large RSR values. The first case has the RSR of 0.083 in the rectum, and the second case has the RSR of 0.154 in the rectum. The replanning for the two cases was then done. Figure 7 shows the comparison of dose distributions and DVHs between the original plans and revised plans for the two cases. As shown in Fig. 7 , significant improvement in rectum and bladder sparing were achieved with the replanning. Table III compares the DEs for the original plans and replans on the two cases. Experimental results showed that the mean doses of the bladder and rectum in the first case are decreased from 19.0 to 15.7 Gy, and from 41.3 to 32.5 Gy, respectively. Likewise, for the second case, the mean doses of the bladder and rectum are decreased from 30.5 to 28.9 Gy, and from 50.5 to 42.3 Gy, respectively. The analysis of sum of residuals DSAR was done to quantify the DVH improvements for these two cases. The result showed that, for the first case, DSAR is 0.036 for the bladder and DSAR is 0.096 for the rectum, and for the second case DSAR is 0.018 for the bladder and DSAR is 0.091 for the rectum, indicating that the sparing of the bladder and rectum was improved.
DISCUSSION
While the output of a DVH predictive model is dosimetric, up to this point, few features characterizing the patients' dosimetric properties have been included in the model input. Indeed, past studies have tacitly ignored the dosimetric properties of the patient and focused on using geometric/anatomical features to construct a correlative model, which may lead to suboptimal prediction due to the intractable and even incomplete dependence of the patient's treatment plan on the selected features. In this work, we have proposed to use the PTV-only plan as a metric to measure the potential for a patient's treatment plan to meet the dosimetric goals and established a machine learning prediction model based on the correlation between the PTV-only plan and the actual CTP for a cohort of patients. Different from these existing knowledge-based planning methods, our technique takes the inherent dosimetric capability property of the patient into consideration and provides a conceptually intuitive and computationally straightforward approach. It should be emphasized that, although DVHs from PTV-only plans were used as the model input in this study, DVHs or other dosimetric features from other different plans, such as OARs sparing-oriented plans, can also be used as the model input to buildup the correlation model.
It is useful to emphasize here that we are not using the features contained in the images or isodose plan to build our predictive model. Instead, the input is related to the potential for the planner to come up with a good plan and to meet the clinical dose-volume constraints. In reality, how to quantify the inherent capability or the likelihood for the OARs to meet their dosimetric goals and utilize the information to facilitate inverse planning is not well understood. This work opens a new avenue of research and development. The formalism is applied to prostate cases to illustrate the technical details of the new predictive model. Our study indicates that the inherent correlation between DVHs from the PTV-only plan and clinical plan is a useful dosimetric feature in prior knowledge modeling and enables an accurate and efficient prediction for the achievable DVHs.
An accurate prediction of achievable DVHs is beneficial for the improvement of the quality of treatment plans, as the predicted achievable DVHs can be used as the starting point for planning of the patient and provide the planner with important guidance in treatment planning. We have demonstrated the effectiveness of the proposed method in predicting achievable DVHs using ten randomly selected cases. In addition to facilitating the treatment planning process, the proposed method can also serve as a quality control tool for treatment planning. The technique provides an effective mechanism to incorporate prior knowledge of the system into the IMRT/VMAT inverse optimization process and enables us to better model the intrastructural trade-off. Compared with the conventional prediction techniques, the proposed method relieves the computation burden of quantifying geometric/anatomical features and provides a more efficient solution to the DVH prediction problem in treatment planning and plan quality control by directly harnessing the high-level dosimetric correlation.
In this study, a database of 63 prostate VMAT plans were used, with 53 cases for training and ten cases for testing. Although our result indicated that the proposed prediction model was favorable as compared with the geometric/ anatomical features-based models, ten testing cases may not be sufficient to fully evaluate the proposed model. Future work will be focused on testing more cases, including the head and neck cases. To train a model, in addition to the CTPs, the corresponding PTV-only plans are also needed as part of the data input. However, the generation of such PTVonly plans is physically intuitive and computationally straightforward as compared with the process of geometric feature extraction aiming at quantifying various geometric/ anatomical features in the existing methods reported in literature. The proposed method simplifies the workflow and enables an efficient DVH prediction.
In comparing the proposed method and the RapidPlan model, the performance was evaluated by examining how close the predicted DVHs are to the CTP DVHs. The better prediction model here was demonstrated by the predicted DVHs closer to the reference DVHs, which were quantified by smaller SAR values. The statistical analysis of SARs in the experiment showed that our method achieved slightly better performance than the RapidPlan model. While the RapidPlan DVHs seemed to provide more OAR sparing (compared with CTP DVHs and the DVHs obtained by using the proposed model, especially for the rectum), their DVHs were not as close to reference DVHs as that of our method. Also, the RapidPlan DVHs may not be achievable compared with the CTPs which were clinical optimized manually. The output of a machine learning model strongly depends on the data used to train the model. Supervised learning represents a classic case of "garbage in, garbage out". When the training database of clinical DVHs are biased or physician dependent, the resultant model in our method would behave the same as other machine learning-based models. Thus, it is critical to ensure that the data used for training the model are unbiased and accurate. If one prefers one trade-off over the other, a physician-specific model can be considered, where the training data are from the same physician.
CONCLUSIONS
In summary, we proposed a novel machine learning framework of DVH prediction for VMAT planning. Our validation study showed the accuracy and effectiveness of the proposed dosimetric features-driven approach, indicating its great potential in clinical applications for improved planning and quality control. Finally, we mention that the technique may find applications in many other disease sites or radiation therapy modalities, such as head and neck, and lung VMAT, Gamma Knife, stereotactic radiosurgery, and other variants of IMRT, including static field and helical IMRT (Tomotherapy).
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